Acurx Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 4
- Market Cap
- -
- Website
- http://www.acurxpharma.com
- Introduction
Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in developing new antibiotics for infections caused by bacteria listed as priority pathogens. Its approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme. Its research and development pipeline includes early-stage antibiotic candidates that target other Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus and Penicillin-Resistant Streptococcus pneumoniae. The company was founded by David P. Luci, Robert G. Shawah and Robert J. DeLuccia in July 2017 and is headquartered in New York, NY.
Clinical Trials
1
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection
- Conditions
- Clostridium Difficile Infection
- Interventions
- First Posted Date
- 2020-01-30
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Acurx Pharmaceuticals Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT04247542
- Locations
- 🇺🇸
Acurx Site #118: Dr Janet Reiser, Scottsdale, Arizona, United States
🇺🇸Acurx Site #115: Dr Neera Grover, Apple Valley, California, United States
🇺🇸Acurx Site #125: Dr Karen Simon, Camarillo, California, United States
News
Acurx Pharma's Ibezapolstat Receives EMA Guidance for Phase 3 C. difficile Infection Program
Acurx Pharmaceuticals received positive guidance from the EMA for its ibezapolstat Phase 3 program, supporting its advancement.
Ibezapolstat Shows Promise in Phase 2 Trial for Clostridioides difficile Infection
Acurx Pharmaceuticals presented Phase 2 trial data for ibezapolstat, an investigational antibiotic, at the Peggy Lillis Foundation Inaugural CDI Scientific Symposium.
Acurx Pharmaceuticals Advances Ibezapolstat for C. difficile Infection
Acurx Pharmaceuticals presented Phase 2 clinical trial results of ibezapolstat for *C. difficile* infection (CDI) at the Anaerobe Society of the Americas, highlighting its clinical efficacy.
Acurx's Ibezapolstat Shows Promise in Phase 2 Trial for C. difficile Infection
Acurx Pharmaceuticals' ibezapolstat demonstrated comparable safety and clinical cure rates to vancomycin in a Phase 2 trial for C. difficile Infection (CDI).
Acurx Pharmaceuticals Announces Positive Trial Results for Ibezapolstat
Acurx Pharmaceuticals reported promising trial results for ibezapolstat, a novel antibiotic targeting Gram-positive bacteria, including Clostridioides difficile.
Acurx Pharmaceuticals' Ibezapolstat Shows High Cure Rate in Phase 2 CDI Trial, Stock Plummets
Acurx Pharmaceuticals announced positive Phase 2 trial results for ibezapolstat in treating C. difficile Infection (CDI), demonstrating a 96% clinical cure rate across Phase 2a and 2b trials.